The Obstacles to Full Adoption and Acceptance of Biosimilars

Modern Medicine Network looks into a whitepaper by the HDA Research Foundation regarding the obstacles to full adoption and acceptance of biosimilars.
Noting that U.S. adoption and approval of biosimilars has been slower than many other nations, including the EU, HDA Research listed a lack of provider awareness and acceptance of biosimilars, an uncertain return on investment, a lack of interchangeability with biologics, coding concerns, and on-going patent disputes as reasons for the slow adoption of biologics.
HDA developed their report following a number of interviews with U.S. specialty distributors and pharmaceutical manufacturers.
Click here to read the story.

Become a Member

Whether you have an established practice, you’re fresh out of your fellowship, or you’re a hospital-based rheumatologist considering private practice, United Rheumatology offers the resources and services you need to advance your career and your clinic.


Find a UR Rheumatologist Near Me

© 2023 United Rheumatology